Published in:
Open Access
01-12-2015 | Research article
The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts
Authors:
Min-Gu Kang, Hye-Ran Kim, Bo-Young Seo, Jun Hyung Lee, Seok-Yong Choi, Soo-Hyun Kim, Jong-Hee Shin, Soon-Pal Suh, Jae-Sook Ahn, Myung-Geun Shin
Published in:
BMC Cancer
|
Issue 1/2015
Login to get access
Abstract
Background
Mutations in genes that are part of the splicing machinery for myelodysplastic syndromes (MDS), including MDS without ring sideroblasts (RS), have been widely investigated. The effects of these mutations on clinical outcomes have been diverse and contrasting.
Methods
We examined a cohort of 129 de novo MDS patients, who did not harbor RS, for mutations affecting three spliceosomal genes (SF3B1, U2AF1, and SRSF2).
Results
The mutation rates of SF3B1, U2AF1, and SRSF2 were 7.0 %, 7.8 %, and 10.1 %, respectively. Compared with previously reported results, these rates were relatively infrequent. The SRSF2 mutation strongly correlated with old age (P < 0.001), while the mutation status of SF3B1 did not affect overall survival (OS), progression-free survival (PFS), or acute myeloid leukemia (AML) transformation. In contrast, MDS patients with mutations in U2AF1 or SRSF2 exhibited inferior PFS. The U2AF1 mutation was associated with inferior OS in low-risk MDS patients (P = 0.035). The SRSF2 mutation was somewhat associated with AML transformation (P = 0.083).
Conclusion
Our findings suggest that the frequencies of the SF3B1, U2AF1, and SRSF2 splicing gene mutations in MDS without RS were relatively low. We also demonstrated that the U2AF1 and SRSF2 mutations were associated with an unfavorable prognostic impact in MDS patients without RS.